AZ’ Forxiga to be reviewed for diabetes type I
PharmaTimes | March 05, 2018
The European Medicines Agency has accepted AstraZeneca’s filing for Forxiga as a treatment for diabetes type I. The submission contains data from the Phase III DEPICT clinical programme, which showed that Forxiga, when given as an oral adjunct to adjustable insulin in patients with inadequately-controlled diabetes type I, induced significant reductions from baseline in HbA1c, weight and total daily insulin dose at 24 and 52 weeks, compared to placebo.